YmAbs Therapeutics (YMAB)
(Delayed Data from NSDQ)
$4.53 USD
+0.06 (1.34%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $4.52 -0.01 (-0.22%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
YMAB 4.53 +0.06(1.34%)
Will YMAB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for YMAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for YMAB
YmAbs Therapeutics (YMAB) Upgraded to Buy: Here's What You Should Know
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates
YMAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates
Anika Therapeutics (ANIK) Reports Q1 Loss, Misses Revenue Estimates
Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates
Other News for YMAB
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
JonesTrading Keeps Their Buy Rating on Y-Mabs Therapeutics (YMAB)